Compare Embla Medical hf with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
DKK 12,391 Million ()
21.00
NA
0.00%
0.42
10.04%
2.06
Revenue and Profits:
Net Sales:
1,662 Million
(Quarterly Results - Jun 2026)
Net Profit:
188 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
539.91%
0%
539.91%
6 Months
539.91%
0%
539.91%
1 Year
539.91%
0%
539.91%
2 Years
539.91%
0%
539.91%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Embla Medical hf for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.75%
EBIT Growth (5y)
15.53%
EBIT to Interest (avg)
5.40
Debt to EBITDA (avg)
1.90
Net Debt to Equity (avg)
0.39
Sales to Capital Employed (avg)
0.72
Tax Ratio
23.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
9.62%
ROE (avg)
7.25%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
1.97
EV to EBIT
16.65
EV to EBITDA
11.13
EV to Capital Employed
1.72
EV to Sales
2.18
PEG Ratio
2.03
Dividend Yield
NA
ROCE (Latest)
10.33%
ROE (Latest)
9.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
1,662.00
1,530.00
8.63%
Operating Profit (PBDIT) excl Other Income
370.00
317.40
16.57%
Interest
35.50
33.40
6.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
188.40
139.00
35.54%
Operating Profit Margin (Excl OI)
161.00%
143.20%
1.78%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 8.63% vs 1.88% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 35.54% vs 0.00% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6,141.40
5,894.90
4.18%
Operating Profit (PBDIT) excl Other Income
1,225.50
1,163.40
5.34%
Interest
139.60
170.60
-18.17%
Exceptional Items
0.00
0.00
Consolidate Net Profit
553.10
475.50
16.32%
Operating Profit Margin (Excl OI)
134.30%
131.90%
0.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4.18% vs 8.86% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 16.32% vs 17.32% in Dec 2024
About Embla Medical hf 
Embla Medical hf
Pharmaceuticals & Biotechnology
Ossur hf is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company is divided into three market segments: Bracing and Supports, which offers products for therapeutic and preventive purposes; Prosthetics, which offers products for amputees, which include sockets, sleeves, prosthetic knees and feet, as well as supporting components, and Compression Therapy, which offers treatment for venous ulcers and edema. The Company's main markets are North America, Europe and Asia. It has subsidiaries in Iceland, the United States, Canada, Mexico, France, the Netherlands, the United Kingdom, Sweden, Norway, Spain, South Africa, China and Australia.
Company Coordinates 
Company Details
Grjothals 1-5 , REYKJAVIK None : 110
Registrar Details






